News
Where Will Medtronic Stock Be in 5 Years?
The past five years haven't been great for medical device maker Medtronic (NYSE: MDT). Normally investors would expect a stock to generate positive gains over a five-year period, but Medtronic's
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while
EQS-News: HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
EQS-Adhoc: Termination of the botulinum toxin project
2 Healthcare Stocks That Could Make You Richer
As far as healthcare stocks go, drugmaker Merck (NYSE: MRK) and medical device expert Intuitive Surgical (NASDAQ: ISRG) haven't been the best of the bunch this year. Both are lagging the market in
Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?
Wall Street traders have numerous (and often creative) strategies to speculate on stocks and their up and down price movements. There are times when the prices of stocks are influenced more by what
EQS-News: Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
CorMedix (CRMD) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q3 2023 Earnings CallNov 14, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Humana Foundation Invests in Innovative Mental Health and Nutrition Programming for Seniors and School-Aged Children
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a series of grants advancing its regional health equity mission by supporting seniors
Better Growth Stock: Pfizer vs. Novo Nordisk
Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with Dexcom Warriors from around the globe to help
Why Rivian Stock Popped 6% on Monday
Shares of electric truck maker Rivian Automotive (NASDAQ: RIVN) gained 5.9% through 2:20 p.m. ET Monday in response to news reports over the weekend that Rivian has secured final approval to build a
Is AT&T Stock a Good Long-Term Investment?
An investment in AT&T (NYSE: T) stock looks appealing on the surface right now given its hefty dividend yield of around 7%. However, the telecom giant's substantial long-term debt load of $126.7
3 Stocks That Can Benefit from a Santa Claus Rally
Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY) are both eyeing the same pie, and they're both serious about getting a big slice. But it isn't a hot market for drugs to treat a single disease
3 Growth Stocks to Buy Right Now Without Any Hesitation
You've probably heard all the old expressions about acting too quickly. "Haste makes waste" and "Look before you leap" are two that readily come to mind. However, there's also danger in waiting too
Where Will Novavax Be in 3 Years?
A lot can happen in just a few years, and Novavax (NASDAQ: NVAX) is the proof of that. Three years ago, the company was rushing toward the coronavirus vaccine finish line -- and the shares were
Why Coherus BioSciences Was Plummeting This Week
A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of
2 Top Biotech Stocks to Buy Right Now
It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's
Got $5,000? Get the Most Bang for Your Buck With These 4%-Plus Dividend Yield Stocks
The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth
AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?
For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q3 2023 Earnings CallNov 09, 2023, 9:00 a.m. ET
Operator
Source Fool.com
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023